Drugs / recombinant interferon a-2B
recombinant interferon a-2B
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04277663 Comparator | Apr 2020 → Feb 2023 | acral lentiginous melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant interferon a-2B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04277663 ↗ |
| Modality | Protein / enzyme biologic | “15\*10\^9 U/m2/d recombinant interferon a-2B intravenously” NCT04277663 ↗ |
| Route | Intravenous | “recombinant interferon a-2B intravenously” NCT04277663 ↗ |